- Home
- ZNTL vs LGI Comparison
ZNTL vs LGI Comparison
Compare ZNTL & LGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- LGI
- Stock Information
- Founded
- ZNTL 2014
- LGI 2004
- Country
- ZNTL United States
- LGI United States
- Employees
- ZNTL N/A
- LGI N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- LGI
- Sector
- ZNTL Health Care
- LGI
- Exchange
- ZNTL Nasdaq
- LGI Nasdaq
- Market Cap
- ZNTL 227.0M
- LGI 210.3M
- IPO Year
- ZNTL 2020
- LGI N/A
- Fundamental
- Price
- ZNTL $2.25
- LGI $16.29
- Analyst Decision
- ZNTL Buy
- LGI
- Analyst Count
- ZNTL 8
- LGI 0
- Target Price
- ZNTL $10.50
- LGI N/A
- AVG Volume (30 Days)
- ZNTL 1.6M
- LGI 41.1K
- Earning Date
- ZNTL 02-25-2025
- LGI 01-01-0001
- Dividend Yield
- ZNTL N/A
- LGI 7.10%
- EPS Growth
- ZNTL N/A
- LGI N/A
- EPS
- ZNTL N/A
- LGI N/A
- Revenue
- ZNTL $40,560,000.00
- LGI N/A
- Revenue This Year
- ZNTL N/A
- LGI N/A
- Revenue Next Year
- ZNTL N/A
- LGI N/A
- P/E Ratio
- ZNTL N/A
- LGI N/A
- Revenue Growth
- ZNTL N/A
- LGI N/A
- 52 Week Low
- ZNTL $2.16
- LGI $12.66
- 52 Week High
- ZNTL $18.07
- LGI $16.68
- Technical
- Relative Strength Index (RSI)
- ZNTL 32.94
- LGI 53.60
- Support Level
- ZNTL $2.16
- LGI $15.59
- Resistance Level
- ZNTL $2.93
- LGI $16.32
- Average True Range (ATR)
- ZNTL 0.28
- LGI 0.20
- MACD
- ZNTL -0.07
- LGI 0.05
- Stochastic Oscillator
- ZNTL 7.69
- LGI 95.89
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt, and others.